As the use of AI spreads through every industry and becomes more of a part of our lives every day, researchers are also ...
Servier today announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback